Scarica l'app Stockscreener
0.2762
6.31%
-0.0186
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Price to sales forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to earnings forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to EBITDA forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Ensysce initiates final stage of opioid overdose protection study By Investing.com - Investing.com Nigeria
Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study - grafa.com
Ensysce initiates final stage of opioid overdose protection study - Investing.com
Ensysce starts final PF614-MPAR study stage for overdose-protection opioid - Stock Titan
Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC) - TradingView
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ensysce Biosciences Inc (ENSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ENSYSCE BIOSCIENCES INC (ENSC) Stock Chart - ChartMill
Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ensysce Biosciences Slips 3.94% as Stock Tests Key Support at $0.23New Listing Stocks - newsline.com
ENSC Q1 2026 Earnings: Narrowing Losses Signal Progress Amid Market VolatilityEarnings Acceleration Picks - lwvtexas.org
Ensysce Biosciences Files for Sale of 1.3 Million Shares - Moomoo
Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale - Stock Titan
ENSC Q1 2026 Earnings: Narrower-Than-Expected Loss Despite No RevenueEarnings Whisper Number - The Legal Advocate
ENSC Q1 2026 Earnings: Narrower-than-expected loss boosts sharesMargin Guidance - newsline.com
Ensysce Biosciences (ENSC) Drops 3% as Stock Nears Support at $0.28MA Crossover - The Legal Advocate
Ensysce Biosciences (ENSC) Declines Further, Tests Key Support Near $0.29Diamond Pattern - Newser
ENSCEnsysce Biosciences Inc Stock Price and Quote - Finviz
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
ENSC Q1 2026 Earnings: Narrower-than-expected Net Loss as EPS Beats EstimatesSegment Revenue Breakdown - The Legal Advocate
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule - Stock Titan
Ensysce Biosciences : Corporate Overview - marketscreener.com
ENSC Advancing Testing and Expanding Potential - Yahoo Finance
Ensysce Biosciences (ENSC) Rallies +0.54% as Bulls Target $0.29 2026-05-18OBV Divergence - Newser
Press Releases about Ensysce Biosciences, Inc.Common Stock - The Chronicle-Journal
Ensysce Biosciences, Inc.Common Stock (Nasdaq:ENSC) Stock Quote - The Chronicle-Journal
Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78 - MSN
Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ensysce biosciences launches formal review of strategic alternativesSEC filing - marketscreener.com
Ensysce Biosciences Launches Formal Review Of Strategic AlternativesSEC Filing - TradingView
Ensysce Biosciences : Earnings Release Q1 2026 - marketscreener.com
ENSC: Clinical milestones and new financing highlight Q1 2026 amid ongoing R&D-driven losses - TradingView
Wider Q1 loss leaves Ensysce (NASDAQ: ENSC) with limited cash runway - Stock Titan
Ensysce Biosciences (ENSC) posts Q1 2026 loss, cash squeeze and strategic review - Stock Titan
This biotech is testing an opioid designed to limit overdose risk - Stock Titan
ENSC Q1'26 Earnings: EPS estimate is (0.73) USD - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Nasdaq most active stocks: - MSN
TradingKey - TradingKey
Ensysce receives Taiwan patent for overdose protection technology - Investing.com UK
Ensysce receives Taiwan patent for overdose protection technology By Investing.com - Investing.com South Africa
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Corsicana Daily Sun
1.53%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):